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Myosin motors are the fundamental force-generating elements of
muscle contraction. Variation in the human β-cardiac myosin heavy
chain gene (MYH7) can lead to hypertrophic cardiomyopathy (HCM),
a heritable disease characterized by cardiac hypertrophy, heart failure,
and sudden cardiac death. How specific myosin variants alter motor
function or clinical expression of disease remains incompletely under-
stood. Here, we combine structural models of myosin from multiple
stages of its chemomechanical cycle, exome sequencing data from two
population cohorts of 60,706 and 42,930 individuals, and genetic and
phenotypic data from 2,913 patients with HCM to identify regions of
disease enrichment within β-cardiac myosin. We first developed com-
putational models of the human β-cardiac myosin protein before and
after the myosin power stroke. Then, using a spatial scan statistic
modified to analyze genetic variation in protein 3D space, we found
significant enrichment of disease-associated variants in the converter,
a kinetic domain that transduces force from the catalytic domain to the
lever arm to accomplish the power stroke. Focusing our analysis on
surface-exposed residues, we identified a larger region significantly
enriched for disease-associated variants that contains both the con-
verter domain and residues on a single flat surface on the myosin
head described as the myosin mesa. Notably, patients with HCM
with variants in the enriched regions have earlier disease onset
than patients who have HCM with variants elsewhere. Our study
provides a model for integrating protein structure, large-scale ge-
netic sequencing, and detailed phenotypic data to reveal insight
into time-shifted protein structures and genetic disease.
hypertrophic cardiomyopathy | myosin | rare disease genetics |
genetic burden
Myosin motors are molecular machines responsible for con-verting chemical energy into the mechanical force necessary
for cell division, directed cell migration, vesicle trafficking, and
muscle contraction (1). Variants in the human β-cardiac myosin
heavy chain gene (MYH7), cause hypertrophic cardiomyopathy
(HCM), a genetic disease of the heart muscle characterized by an
asymmetrical thickening of the ventricular walls and a decrease in the
ventricular chamber size. HCM is the most common heritable heart
disease, with a prevalence of one in 500 individuals (2). Clinically, the
course of HCM is variable, with some patients experiencing
minimal symp-toms and others developing arrhythmia, heart
failure, or sudden death (3). Relationships between genotype and
disease expression in HCM have been challenging to establish due
to the absence of large-scale genetic population data and lack of
multicenter sharing of patient genetic and clinical data (4, 5).
TheMYH7 gene is highly constrained for genetic variation (6).
Few loss-of-function variants are observed in population cohorts,
and identified pathogenic variants are mainly missense. However,
although many missense genetic variants inMYH7 cause HCM, not
all genetic changes within the gene lead to disease. There are
competing hypotheses regarding the localization of pathogenic
missense variants within MYH7, analysis of which can offer insight
into the underlying mechanism of HCM. Investigators have sug-
gested enrichment of pathogenic variants in many of the functional
domains of β-cardiac myosin, including the converter domain,
actin-binding site, and ATP-binding domain (7–9). However,
others have suggested there is no regional enrichment for HCM
variation within MYH7 (4, 10). These inconsistencies could be
due to limited sample sizes or to a lack of reference cohorts for
comparison. Without information about the natural distribution
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of rare variants within MYH7, it is impossible to distinguish
regions of disease-variant enrichment from regions of increased
genetic tolerance (11). In addition, some putatively pathogenic
variants are later found at higher than expected allele frequen-
cies in large, ethnically diverse population reference cohorts
(12). The study suggesting enriched domains lacked reference
cohorts; when a reference cohort was compared against genetic
variants from a small sample of patients with HCM, the study
failed to detect any significant enrichment for disease-associated
variants (10). In addition, a focus on the linear sequence of the
gene or previously discovered functional domains could overlook
novel functional regions or enrichments spanning multiple do-
mains. These discrepancies point to the need to test for regional
HCM variant enrichment withinMYH7 using both a large patient
population and a large reference cohort while also accounting for
the 3D structure of β-cardiac myosin.
Recent advances in next-generation sequencing technology
have enabled the assembly of large datasets of human genetic
variation in both unselected and disease-affected populations.
Comparative analysis of these cohorts enables within-gene inference
of disease burden and constraint, a measure of population tolerance
to variation that can reveal insight into critical functional residues
and disease etiology. The Exome Aggregation Consortium (ExAC)
(13) and the DiscovEHR (14) cohort are exome sequencing cohorts
of 60,706 and 42,930 individuals, respectively, that provide detailed
information regarding the rates and types of genetic variation seen
within disease genes. In addition, the Sarcomeric Human Cardio-
myopathy Registry (SHaRe) was established as an international
consortium of HCM investigators and currently contains detailed
longitudinal clinical data on 2,913 patients with HCM who have
undergone genetic testing. As large clinical and population se-
quencing projects such as these become more prevalent, novel
methods for statistical analysis of variant burden and constraint
will be essential for gaining insight into disease and identifying
intragene regions enriched from disease-associated variation.
We hypothesized that assessing regional genetic tolerance in
the context of time-shifted 3D structures would reveal novel in-
sights into MYH7 and possible hot spots in the myosin structure of
pathogenic variants within HCM. Here, we compare genetic data
from the SHaRe, an international HCM registry (15), with variants
identified in large-scale exome sequencing projects (13) to identify
regions of enrichment for HCM-associated variation within pre-
and poststroke structures of β-cardiac myosin. In addition, we de-
velop a general statistical framework based on a modified version
of a spatial scan statistic to search for regions of increased disease-
associated variation in 3D protein structures and surfaces. Finally,
we take advantage of the clinical and phenotypic data in the
SHaRe to examine clinical differences between groups of patients
based upon variant location within β-cardiac myosin. We demon-
strate the power of combining clinical, genetic, and structural data
to make inferences regarding disease etiology and 3D structural
hotspots for HCM variants.
Results and Discussion
We first compared the linear distribution of missense variants in
patients with HCM (SHaRe) with missense variants in a population
reference cohort (ExAC). The ExAC cohort contains sequencing
information from 60,706 individuals who were part of disease-spe-
cific (non-HCM) and population genetic studies, and the SHaRe
database contains 2,913 individuals with HCM sequenced forMYH7.
Although the ExAC reference contains some pathogenic sarcomere
variants and likely some individuals with HCM, it is not enriched for
individuals with the disease. We found 192 unique missense variants
(in 474 patients with MYH7 variants) in the HCM cohort and 421
unique missense variants in the ExAC database (Dataset S1). In
both cases, observed missense variants were very rare and the ma-
jority were observed only once (Fig. 1), consistent with previous
reports of constraint within the MYH7 gene (6). Further, the vast
majority of SHaRe patients with a rare variant in MYH7 carry only
one such variant (457 of 474 patients), whereas 16 carry two rare
missense variants and a single patient carries three different variants.
Both disease (SHaRe) and population/reference (ExAC)
variants are nonuniformly distributed throughout the gene, and
we find a significant difference in the linear distribution of rare
variants between these cohorts [Kolmogorov–Smirnov (KS) test:
P = 5.0 × 10−11; Fig. 1]. Disease-associated missense variants are
concentrated in the catalytic globular domain and the coiled-coil
S2, consistent with some previous results (4) but in contrast to
other recent comparisons (10). Even within these domains,
however, distributions of disease and population variants are not
the same (KS test: P = 0.003). In addition, missense variants in
MYH7 in both the SHaRe and ExAC cohorts are extremely rare;
the majority in both cohorts are observed only once (Fig. 1 B and
C). These results suggest that the likelihood of MYH7 variants
causing disease is due, in part, to their location within the gene.
Because molecular motors act in 3D space, we sought a method
to investigate patterns of genetic tolerance in the folded structure of
human β-cardiac myosin protein. We used multitemplate homology
modeling of other myosin proteins in the pre- and poststroke states
to build 3D models of human β-cardiac myosin containing the hu-
man ventricular light chains (Fig. 2 and Materials and Methods).
These models represent two distinct phases of the actin-activated
myosin chemomechanical cycle. Four fundamental regions of the
myosin motor domain are included: the actin-binding site (Fig. 2,
green residues), the ATP-binding pocket (red), the converter
domain (blue), and the light chain-binding region or lever arm.
In the prestroke state, the converter aligns with a relatively flat
surface of the myosin head described as the myosin mesa. Based
on its size (>20 nm2), flat topology, and high degree of evolu-
tionary conservation, this feature has been proposed as an in-
teraction site for intra- or intermolecular binding (16). Following
the force-producing lever arm stroke of a myosin head, the
motor is in its poststroke state (Fig. 2A) and the mesa falls out of
alignment with the converter domain.
To identify 3D structural regions of interest, we applied a
modified version of the spatial scan statistic (17, 18) to the prestroke
and poststroke models of β-cardiac myosin S1. This statistic searches
for spherical regions with an increased proportion of genetic variants
in disease compared with reference cohorts. We defined any rare
missense variants observed in patients with HCM in theMYH7 head
as disease-associated (n = 103) and any variants seen only in the
ExAC cohort as reference (or population) variants (n = 110).
Twenty-two variants observed in both the SHaRe and ExAC
cohorts were classified as disease-associated. In the myosin pre-
stroke model, we find a striking increase in the proportion of
disease-associated missense variation in a 15-Å sphere centered
Fig. 1. Differences in the position of missense variants between HCM and
population reference cohorts in human β-cardiac myosin. (A) Missense variants
identified in SHaRe HCM patients are shown in red, and missense variants iden-
tified in ExAC individuals are shown in blue. The height of each point is offset for
visibility. (B) Minor allele count of MYH7 missense variants observed in SHaRe
HCM probands. (C) Minor allele count of MYH7 missense variants in the ExAC
database. Fifteen missense variants with a frequency above 0.005 are not shown.
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on residue 736 (P = 0.001) (Fig. 3A and Dataset S2). This region,
covering a subset of the converter domain, contains 17 missense
variants observed in disease and no missense variants observed in
reference data (Fig. 3C). Using the poststroke model of β-cardiac
myosin, we again observed enrichment of disease-associated vari-
ants in a portion of the converter domain (P < 0.001) centered on
residue 733 (Fig. S1).
Enrichment of disease-associated variants in both the pre- and
poststroke states persists when including only variants formally
classified as pathogenic or likely pathogenic (26 disease-associated
of 103 total variants in the SHaRe; Supporting Information). Burden
tests can also be sensitive to differences in the population preva-
lence of disease or differences in the population frequency of var-
iants. To ensure that our results were robust to these potential
biases, we performed the same analysis limited to individuals of
European descent, the largest population in both the SHaRe and
ExAC cohorts (2,519 of 2,913 patients in the SHaRe and 89 of 103
disease-associated variants; Supporting Information). We identified
very similar enriched regions in both the pre- and poststroke
models, indicating that our analysis is not being significantly af-
fected by population stratification. However, large cohorts from
other populations may help identify other regions of the myosin
enriched for disease variation.
During systolic contraction of the heart, the converter domain
serves the critical function of transducing force by swinging about
70° from its prestroke position (Fig. 3B, lever arm projecting
outward). Variants in the converter domain have been shown to
alter muscle power output and kinetics (19, 20) and have been
associated with worse outcomes in HCM (21, 22). We find that
the converter domain is the only spherical region significantly
enriched for disease variation in contrast to previous reports,
which hypothesized that there were many regions of enrichment
throughout the myosin head (7–9) or others that found no regions
of significant enrichment (10). Although location in an enriched
region is not a necessary condition for pathogenicity, novel variants
in regions strongly enriched for disease variation should be viewed
with increased suspicion. In regions where nearby variants do not
have similar effects, there will not be an enrichment of disease-
associated variation. Our data provide a complementary line of
evidence that variants in part of the β-cardiac myosin converter
domain are poorly tolerated and individuals carrying variants in
this region are prone to development of HCM.
To replicate these results, we sought an independent source of
disease-associated and population genetic variation. We curated
publications from medical centers not yet affiliated with the
SHaRe registry (Dataset S3 and Supporting Information). We com-
pared this set of 231 unique missense variants with 430 unique
missense variants found in 42,930 exomes from unselected individ-
uals in the Geisinger Health System sequenced by the Regeneron
Genetics Center (DiscovEHR cohort) (14) (Dataset S4). The
converter domain regions identified in both the prestroke and
poststroke states showed enrichment of disease-associated vari-
ants in the replication dataset (prestroke: P = 0.0079, poststroke:
P = 4.1 × 10−4).
Surface regions of the β-cardiac myosin have been suggested
to be important functional domains implicated in HCM (16). We
extended our analysis to examine surface regions of β-cardiac
myosin and search for regions enriched for HCM-associated var-
iants. We first defined surface-exposed amino acids by their ac-
cessibility to a spherical probe with a radius of 2.5 Å (the approximate
size of an amino acid side chain) and approximated the surface dis-
tance between any two residues (23) (Supporting Information). As
expected, surface distances tended to be shorter between amino acids
nearby in the primary sequence (Fig. S2B, diagonal). In addition,
there were many regions where amino acids far apart in the primary
Fig. 2. Structural models of the human β-cardiac post- and prestroke
obtained by integrating data from solved crystal structures of homologous
models. (A) Side view of myosin S1, with the relatively flat mesa at the top, in
the poststroke state with important functional domains labeled: the actin-
binding site (green residues), the ATP-binding pocket (red), the converter
(blue), and the light chain-binding region or lever arm. The converter and its
associated lever arm are behind the plane of the figure and below the level
of the mesa. (B) Myosin S1 in the prestroke state. Small changes within the
globular head region with ADP and Pi in the nucleotide pocket result in a
large ∼70° rotation of the converter and lever arm. The converter is moved
forward and up compared with the poststroke structure, and the lever arm is
projecting forward out of the plane of the image. The distance traversed by
the C-terminal end of the lever arm is ∼10 nm, the stroke size of the motor.
Fig. 3. Spatial scan statistic identifies a spherical region of the converter do-
main with an increased proportion of HCM-associated variants. (A) Same side
view of the prestroke S1 motor domain as shown in Fig. 1B, without the light
chains attached to the α-helical light chain-binding region of the S1. The orange
residues define a sphere of residues in the motor domain, which is the only
region significantly enriched for HCM variants. The S1 residues are colored as
follows: orange, region enriched for HCM variants; blue, missense variants seen
only in the ExAC; red, missense HCM variants seen in the SHaRe; light gray, all
other residues. (B) Enriched region in the prestroke model of myosin from a
different perspective. The view is directly down onto the surface. Coloring is as
in A. (C) Number of HCM-variants (SHaRe) and non–disease-associated (ExAC)
variants identified in the spherical enriched region (Left) and in the sum of all
other parts of the myosin (Right).
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sequence were close together on the surface of the β-cardiac myosin
(e.g., amino acids near residues 110 and 684).
The surface of β-cardiac myosin contains 568 of the 765 residues
in the S1 domain (74%). Of these residues, 71 are associated with
HCM (72% of all HCM variants) and 79 are found in the ExAC
population (71% of all reference variants), suggesting that variants
in both cohorts are evenly distributed between the surface and core
of the protein (χ2: P = 0.51). We then applied our spatial scan
statistic to the surface of β-cardiac myosin. Using the myosin pre-
stroke model, we identified a region of the surface covering 277 of
the 568 surface amino acid residues (P = 0.002; Fig. 4 A and B),
including the converter domain and the mesa, which is highly
enriched for disease-associated variation. Strikingly, the region
contains 52 of the 71 surface HCM-associated missense variants
and only 27 of the 79 surface non–disease-associated missense
variants (Fig. 4D), whereas the remainder of the myosin surface
(Fig. 4C) covers 291 residues and contains only 19 disease-associated
variants compared with 52 non–disease-associated variants (Fig.
4D). The identified converter/mesa region was also enriched in the
replication dataset (P = 4.3 × 10−5).
Using the same procedure to search the surface regions of the
myosin poststroke structure, we detected a smaller enriched re-
gion of 122 amino acid residues again covering the converter but
with a reduced portion of the myosin mesa (Fig. S3), a domain
that has been proposed to be a binding site for another protein
structural element (16). During the myosin power stroke, the
converter moves away from the mesa (compare Figs. 2 A and B,
2B, and 4 and Fig. S3), so the enriched converter/mesa region is
no longer contiguous and available for intra- or intermolecular
interactions in the poststroke state (Fig. 2B and Fig. 4 A and B).
The enriched amino acid residues in the poststroke model move
significantly more in 3D space between the pre- and poststroke
models (Wilcoxon test: P < 2 × 10−16) than other amino acid
residues on the surface of the protein. This result suggests that
myosin conformational changes during the actin-activated che-
momechanical cycle may be important not only for transducing
force but also for modulating the size and shape of this surface
region and altering its availability for binding to other protein
structural elements. The functional importance of the converter
and the mesa region is further supported by the presence of the
binding site for omecamtiv mecarbil, a recently described small-
molecule modulator of cardiac myosin currently in clinical trials
for the treatment of heart failure (24, 25).
Next, we tested the myosin S2 fragment for regions enriched
for disease-associated variation. The spatial scan analysis revealed
that the first half of the S2 fragment is enriched for disease
variants (P = 0.003; Fig. S4). This proximal part of S2 has been
shown to bind to the aminoterminal part of myosin-binding
protein C (MyBP-C) (26), a sarcomere protein that is also fre-
quently mutated in patients with HCM (27). The enrichment of
disease-associated variants in this region suggests that binding
between myosin S2 and MyBP-C (and potentially other partners)
is important for development of HCM.
To investigate the contribution of the genetically constrained
regions to disease further, we compared the clinical features of
patients with variants in these regions with the clinical features of
patients with variants elsewhere in MYH7. The clinical profile
of HCM is highly variable, with some patients living a normal
lifespan with minimal symptoms and others dying suddenly or
requiring cardiac transplantation at a young age (28). Similarly,
age at presentation of HCM varies widely among patients, and
earlier onset is correlated with a more severe phenotype (29).
We find that HCM patients with a variant inside the spherical
enriched region are 11.2 y younger at diagnosis [24.9 (SE = 1.0)
vs. 36.1 (SE = 1.2) y old; P = 5.6 × 10−5; Fig. 5 A and B] than
patients harboring other variants in the myosin head. The pres-
ence of a variant in the HCM-enriched surface region is asso-
ciated with a 10.0-y younger age at diagnosis [31.5 (SE = 2.4)
vs. 41.5 (SE = 2.6) y old; P = 1.6 × 10−4] than in those patients
with other surface variants (Fig. 5 C and D). In addition, we find
an increased hazard for clinical outcomes in the surface enriched re-
gion after adjusting for differences in age at diagnosis (hazard ratio =
1.918, P = 0.023), although not in the spherical enriched region
(Fig. S5 and Supporting Information). These findings demonstrate
that analysis of genetic constraint in protein space can reveal do-
mains with both increased disease burden and pathogenicity.
Our study demonstrates the power of integrating detailed
structural information with large clinical and genetic databases to
identify regions associated with functional importance and disease
severity in Mendelian diseases. We find that variants associated with
HCM are enriched in the β-cardiac myosin converter domain,
where they lead to more severe outcomes. We provide the first
evidence, to our knowledge, that similar clustering and pathoge-
nicity are present in a surface spanning the converter domain and
the relatively flat surface of the myosin catalytic domain called the
myosin mesa (16). Because amino acid residues forming the mesa
come from disparate locations in the nucleotide sequence, discovery
of this region depends on integration of protein structural in-
formation. The pronounced shift of the converter/mesa surface
during the power stroke raises the mechanistic hypothesis that these
variants exert their deleterious effect selectively in the prestroke
state, perhaps by disrupting dynamic binding interactions. In sum-
mary, these findings highlight the importance of considering data
from human genetics in the context of the dynamic 3D protein
structure, and illustrate an approach to structure/function analysis in
genetic diseases.
Materials and Methods
SHaRe Database. The SHaRe is a multicenter database that pools deidentified
patient-level data from established institutional datasets at participating
sites. At the time of analysis, the registry contained clinical and genetic testing
data on 2,913 patients with HCM, 514 with variants in MYH7. This database
contains individuals from nine inherited disease centers throughout the
world and includes demographic data, medical history, echocardiogram
data, genetic testing results, and many other data relating to cardiac health
and clinical outcomes.
Fig. 4. Surface spatial scan analysis identifies a larger surface region enriched
for HCM-associated missense variation. (A) Similar view of the prestroke model
to the view in Fig. 2B, looking directly down onto the mesa. The residues are
colored as follows: orange, surface region enriched for HCM variants; blue,
missense variants seen only in the ExAC; red, missense variants seen in the
SHaRe; light gray, residues considered to be on the surface; dark gray, residues
not considered to be on the surface. The HCM-enriched surface region identi-
fied covers the entire mesa plus the adjoining converter domain. (B) Same side
view of the prestroke S1 motor domain as shown in Figs. 1 and 2A. (C) View
of the prestroke model viewing the side opposite the mesa. This surface is
not enriched for HCM variants. (D) Number of HCM variants (SHaRe) and non–
disease-associated (ExAC) variants identified in the surface enriched region
(Left) and in the sum of all other parts of the myosin surface (Right).
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ExAC. The ExAC (13) released data from 60,706 exomes from multiple se-
quenced cohorts that are not enriched for rare diseases such as HCM. We
downloaded ExAC data for the canonicalMYH7 transcript ENST00000355349
on August 27, 2015.
Variant Filtering and Inclusion Criteria. Variants in MYH7 from the SHaRe
database were filtered for quality purposes. Only exonic missense variants in
MYH7 were included in the analysis. We included all exonic missense variants
seen in HCM patients in clinical genetic testing. For comparison, we downloaded
data from the MYH7 gene from the ExAC on August 27, 2015.
For the spatial scan and surface scan analyses, variants were considered to
be one of two categories: disease-associated and reference. Any raremissense
variants identified in HCMpatients in the SHaRe cohort were considered to be
disease-associated, regardless of their presence in the ExAC population. Rare
missense variants identified only in the ExAC population were considered to
be non–disease-associated, or reference, variants. Any variants identified in
both the SHaRe and ExAC cohorts were considered to be disease-associated.
Within the MYH7 S1 head, we identified 103 disease-associated variants
(seen in the SHaRe) and 110 reference (or population) variants seen only in
the ExAC cohort. Twenty-two variants observed in both the SHaRe and ExAC
cohorts were classified as disease-associated.
Enrichment testing was performed by searching for regions of the myosin
protein that had a significantly higher proportion of disease-associated variants
than non–disease-associated variants. The ExAC population likely contains some
individuals with cardiomyopathy induced by changes in MYH7; therefore, we
cannot assume variants identified in the ExAC are not pathogenic. For example,
there are multiple individuals carrying a well-known pathogenic variant for
HCM in the MYBPC3 gene, p.Arg502Trp, in the ExAC cohort. However, the
incidence of cardiomyopathies in the ExAC population is not expected to be
greater than the incidence in the general population. A large proportion of the
rare variants identified in MYH7 in the ExAC cohort are likely not associated
with cardiomyopathy. In contrast, rare variants identified in SHaRe HCM pa-
tients are likely enriched for disease-causing variation.
We calculated the maximum population-specific allele frequency for each
variant in the ExAC as the maximum frequency of the variant in any of the ExAC
populations (excluding Finnish). To compare the burden of rare variants within
each cohort, we removed from both sets (SHaRe and ExAC) any allele with a
population-specific allele frequency higher than 1:2,000. This filter removed 16
variants inMYH7 from our ExAC list (of 421 total variants), six of which were also
reported in the SHaRe list (of 192 total variants). Within the MYH7 head, only
four ExAC variants were found at a higher frequency than 1:2,000 (of 136 total
variants), two of which were also seen in the SHaRe cohort (of 105 total variants).
For validation purposes, we also performed a subset of analyses including
variants classified as “pathogenic” or “likely pathogenic” according to the
American College of Medical Genetics and Genomics guidelines (30), although
excluding variants of unknown significance, likely benign, and benign variants
(Supporting Information). In addition, we performed a validation analysis using
variants found in individuals of European ancestry from the ExAC and indi-
viduals with a reported race of white to ensure that global population structure
was not confounding our analysis (Supporting Information).
We generated an independent validation dataset combining previously
published analyses of HCM variants from other medical centers with 42,930
exomes from the DiscovEHR sequencing project (14). We included only missense
variants and removed variants with an allele frequency greater than 1 in 2,000
in the DiscovEHR exomes (Supporting Information).
Development of Human β-Cardiac Myosin Protein Models.Wedeveloped human
β-cardiac myosin S1 models based on the knownmotor domain structural data to
represent the human form of the cardiac myosin. We retrieved the protein se-
quence of human β-cardiac myosin and the human cardiac light chains from the
UniProt database (31): myosin heavy chain motor domain (MYH7), P12883; my-
osin essential light chain (MLC1), P08590; and myosin regulatory light chain
(MLC2), P10916. We used a multitemplate homology modeling approach to build
the structural coordinates ofMYH7 (residues 1–840), MLC1 (residues 1–195), MLC2
(residues 1–166), and S2 (residues 841–1,280). We obtained the 3D structural
model of S1 in the pre- and poststroke states by integrating the known
structural data from solved crystal structures (details are provided in Sup-
porting Information). Homology modeling of the prestroke structure was
performed with template structures of the smooth muscle myosin motor
domain (32) [Protein Data Bank (PDB) ID code 1BR1; with MgADP.AlF4
bound at the active site, which is thought to mimic most closely the ADP.Pi-
bound state, or prestroke state, of the myosin] and the scallop smooth
muscle myosin light chain domain (33) (PDB ID code 3TS5). The templates
used for the modeling of the poststroke structure were obtained from the
human β-cardiac myosin motor domain (25, 34) (PDB ID code 4P7H; no nu-
cleotide in the active site) and the rigor structure from the squid myosin
motor domain (35) (PDB ID code 3I5G; no nucleotide in the active site).
Modeling was done using the MODELER package (36). Visualizations were
performed using PyMOL version 1.7.4 (www.pymol.org).
Statistical Methods. Comparisons between the ExAC and SHaRe variant loca-
tions inMYH7were performed using the KS test statistic. All statistical analyses
were performed in R version 3.1.2 (37), and many graphs were prepared using
ggplot2 (38).
Spatial Scan Statistic. For the spatial scan analysis, we compared the locations
of unique HCM-associated variants with the locations of reference variants.
The spatial scan statistic exhaustively searches 3Dwindows of a predefined set
of sizes and shapes throughout the human β-cardiac myosin molecule for
regions with an increased proportion of HCM-associated variants. It identifies
the 3D region of the protein with the largest binomial likelihood ratio test of
enrichment of HCM-associated variants (17, 18) (Supporting Information). The
maximum binomial ratio test statistic for the entire set of windows in themodel
was calculated, and significance was assessed through permutation of variant
labels using 1,000 permutations. For validation, we performed the analysis
above, removing all missense variants classified as variants of unknown signifi-
cance using only missense variants observed in the European individuals
(Supporting Information).
Surface Analysis. In addition to the spherical windows defined above, we define
windows based upon the exposed surface of the human β-cardiac myosin mole-
cule. For this analysis, we estimate the surface distance between any two amino
acids based upon the solvent-excluded surface calculated by the MSMS program
(23) (Supporting Information). Based upon this set of pairwise calculated dis-
tances, we define planar surface regions of the β-cardiac myosin for analysis as all
of the amino acids within a certain distance of any given “center” amino acid.
Fig. 5. Comparison of clinical phenotypes between enriched regions and
other regions in β-cardiac myosin. (A) Age of diagnosis of patients with HCM
variants in the enriched spherical converter region (orange, n = 45) compared
with patients with variants in other parts of the myosin head (blue, n = 201)
(Wilcoxon test: P = 6.7 × 10−5). Box plots show the median surrounded by the
interquartile range (IQR), with whiskers extending to 1.5-fold the interquartile
range (IQR). (B) Kaplan–Meier curves of age at diagnosis compared between
HCM variants in the enriched spherical converter region (orange) and patients
with variants in other parts of the myosin head (blue). Shading indicates 95%
confidence intervals for the survival curve. (C) Age of diagnosis of patients with
HCM variants in the enriched surface region (orange, n = 145) compared with
patients with variants in other parts of the myosin head surface (blue, n = 46)
(Wilcoxon test: P = 1.6 × 10−4). Box plots show the median and IQR, with
whiskers extending to 1.5-fold the IQR. (D) Kaplan–Meier curves of age at di-
agnosis compared between HCM variants in the enriched surface region (or-
ange) and patients with variants in other parts of the myosin head surface
(blue). Shading indicates 95% confidence intervals for the survival curve.
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We exclude nonsurface amino acids, based upon their depth. We once again
perform the spatial scan statistic as described above to identify surface regions
of increased genetic burden.
S2 Fragment Analysis. We performed the spherical spatial scan statistic as de-
scribed above to test for enrichment in the S2 fragment of myosin, including the
region between amino acids 838 and 1,112 (Supporting Information).
Clinical Phenotype Analysis. For the analysis of age at diagnosis, only known
probands were included (n = 260 myosin head, n = 201 myosin surface). Patients
with multiple MYH7 variants were excluded from the age at diagnosis analysis,
because the presence of multiple variants causes an earlier onset of HCM. We
compared the primary diagnosis ages using a Wilcoxon test. The overall com-
posite outcome combined the arrhythmic and heart failure outcomes, as well
as the outcomes of atrial fibrillation, stroke, and all-cause death (Supporting
Information). Individuals were considered to enter the study at their diagnosis
age and were censored at their last known age. We compared hazard ratios for
each region using the Cox proportional hazards model, adjusting for gender.
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